AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Core Points - AIM ImmunoTech Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, NY, which focuses on industry trends and advancements [1] - Management will be available for in-person one-on-one meetings with registered investors during the conference [2] - AIM ImmunoTech is an immuno-pharma company developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen, currently in Phase 2 clinical trials for metastatic pancreatic cancer in collaboration with AstraZeneca [4] Company Information - AIM ImmunoTech Inc. specializes in research and development of therapeutics targeting multiple diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist [4] - AIM ImmunoTech is focused on broad-spectrum activity in clinical trials, particularly in combination therapies for cancer treatment [4] Event Information - The Maxim Growth Summit is organized by Maxim Group LLC, a full-service investment banking and wealth management firm based in New York [3] - The summit will feature industry leaders and innovators discussing the latest trends across various sectors [1] - For more details on the summit agenda and AIM's presentation, interested parties can visit the respective websites [2]